Having reached a number of critical milestones throughout 2018, Epigenomics reported FY2018 product sales of 0.8m (47% YoY), highlighting the company's strong underlying growth momentum. While total sales of €1.5m (-18% YoY) were slightly below our revenue expectations, largely due to a reduction in licensing revenue associated with a one-off patent sale in Q4/2017, product sales in Q4/2018 increased by 7% YoY. We are revising our sales forecasts for FY2019E and out-years as a result of the rece ....
28 Mar 2019
2018 results highlight strong underlying growth momentum
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2018 results highlight strong underlying growth momentum
Epigenomics AG (0QXH:LON) | 0 0 0.0% | Mkt Cap: 24.5m
- Published:
28 Mar 2019 -
Author:
Martin Piehlmeier -
Pages:
9
Having reached a number of critical milestones throughout 2018, Epigenomics reported FY2018 product sales of 0.8m (47% YoY), highlighting the company's strong underlying growth momentum. While total sales of €1.5m (-18% YoY) were slightly below our revenue expectations, largely due to a reduction in licensing revenue associated with a one-off patent sale in Q4/2017, product sales in Q4/2018 increased by 7% YoY. We are revising our sales forecasts for FY2019E and out-years as a result of the rece ....